Arvinas is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC⢠protein degraders, that are designed to harness the bodyâs own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Source
No articles found.
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and ther...
Alseres Pharmaceuticals, Inc. is focused on the...
Rubius Therapeutics developed our proprietary RED PLATFORMÂŽ to generate red blood...
Rubius Therapeutics developed our proprietary R...
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...
bluebird bio is pioneering gene therapy with pu...
Join the National Investor Network and get the latest information with your interests in mind.